You missed the point. Given pphm credibility issues ($1.31 speaks volumes to that) why are they so vague about enrollment. They say on plan but the plan is not linear and back-end loaded to an unknown degree. There are many trials with much more pr/exposure, being written about everywhere; so of course people are concerned that the enrollment is robust. If the enrollment is where you think it is what would pphm announcing those as hard numbers do to share price?
News 
Market Data 
Discover 
